Phosphoglycerol dihydroceramide, a distinctive ceramide produced by Porphyromonas gingivalis, promotes RANKL-induced osteoclastogenesis by acting on non-muscle myosin II-A (Myh9), an osteoclast cell fusion regulatory factor

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 May;1862(5):452-462. doi: 10.1016/j.bbalip.2017.01.008. Epub 2017 Jan 31.

Abstract

Among several virulence factors produced by the periodontal pathogen Porphyromonas gingivalis (Pg), a recently identified novel class of dihydroceramide lipids that contains a long acyl-chain has the potential to play a pathogenic role in periodontitis because of its higher level of tissue penetration compared to other lipid classes produced by Pg. However, the possible impact of Pg ceramides on osteoclastogenesis is largely unknown. In the present study, we report that the phosphoglycerol dihydroceramide (PGDHC) isolated from Pg enhanced osteoclastogenesis in vitro and in vivo. Using RAW264.7 cells, in vitro assays indicated that PGDHC can promote RANKL-induced osteoclastogenesis by generating remarkably larger TRAP+ multinuclear osteoclasts compared to Pg LPS in a TLR2/4-independent manner. According to fluorescent confocal microscopy, co-localization of non-muscle myosin II-A (Myh9) and PGDHC was observed in the cytoplasm of osteoclasts, indicating the membrane-permeability of PGDHC. Loss- and gain-of-function assays using RNAi-based Myh9 gene silencing, as well as overexpression of the Myh9 gene, in RAW264.7 cells showed that interaction of PGDHC with Myh9 enhances RANKL-induced osteoclastogenesis. It was also demonstrated that PGDHC can upregulate the expression of dendritic cell-specific transmembrane protein (DC-STAMP), an important osteoclast fusogen, through signaling that involves Rac1, suggesting that interaction of PGDHC with Myh9 can elicit the cell signal that promotes osteoclast cell fusion. Taken together, our data indicated that PGDHC is a Pg-derived, cell-permeable ceramide that possesses a unique property of promoting osteoclastogenesis via interaction with Myh9 which, in turn, activates a Rac1/DC-STAMP pathway for upregulation of osteoclast cell fusion.

Keywords: DC-STAMP; Non-muscle myosin II-A; Phosphoglycerol dihydroceramide; Porphyromonas gingivalis; RANKL-induced osteoclastogenesis; Rac1 small GTPase.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Communication / genetics
  • Cell Differentiation / genetics
  • Ceramides / chemistry
  • Ceramides / genetics
  • Ceramides / metabolism*
  • Gene Silencing
  • Glycerophospholipids / metabolism
  • Humans
  • Membrane Proteins / genetics
  • Mice
  • Myosin Heavy Chains
  • Nerve Tissue Proteins / genetics
  • Nonmuscle Myosin Type IIA / genetics*
  • Nonmuscle Myosin Type IIA / metabolism
  • Osteoclasts / metabolism
  • Osteoclasts / pathology
  • Osteogenesis / genetics
  • Periodontitis / genetics*
  • Periodontitis / microbiology
  • Periodontitis / pathology
  • Porphyromonas gingivalis / metabolism*
  • Porphyromonas gingivalis / pathogenicity
  • RANK Ligand / metabolism
  • RAW 264.7 Cells
  • Signal Transduction / genetics
  • rac1 GTP-Binding Protein / genetics

Substances

  • Ceramides
  • DC-STAMP protein, mouse
  • Glycerophospholipids
  • Membrane Proteins
  • Myh9 protein, mouse
  • Nerve Tissue Proteins
  • RANK Ligand
  • Tnfsf11 protein, mouse
  • dihydroceramide
  • Nonmuscle Myosin Type IIA
  • Myosin Heavy Chains
  • rac1 GTP-Binding Protein